1. Medtech Insight
  3. >>R&D
  4. >>Clinical Trials

Mainstay Will Supplement Australian ReActiv8 Application With ReActiv8 B Data

 
• By Reed Miller

Australia's Therapeutic Goods Administration asked for additional clinical data on Mainstay Medical's ReActiv8 neurostimulation device for chronic low-back pain, so the company will provide clinical data from the ongoing ReActiv8 B trial.

ReActiv8
Mainstay Medical's ReActiv8 neurostimulator for chronic low-back pain • Source: Mainstay Medical

Data from the US ReActiv8 B trial of Mainstay Medical International PLC's ReActiv8 neurostimulator to treat low-back pain will supplement the company's regulatory application in Australia.

The Irish company announced on April 5 that Australia's Therapeutic Goods Administration has requested additional clinical data supporting the regulatory...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Medtronic’s ‘Strategic Expansion’ Into Remote Monitoring

 
• By Natasha Barrow

“The Corsano wearable strengthens Medtronic’s acute care and monitoring portfolio,” Marc De Martini, vice president at Medtronic, told Medtech Insight.

European Commission Asks For ‘Open Minds’ On Unified Drug/Device Research Pathway

 
• By Vibha Sharma

As the EU tests the feasibility of a radical “all-in-one” procedure for combined drug and IVD studies, sponsors are being urged to approach this novel framework with flexibility and openness.

No Strings Attached: Big Players Chase Insulet In Fast-Growing Tubeless Insulin Pump Market

 
• By Marion Webb

Medtronic, Tandem and Beta Bionics are gearing up to bring tubeless patch pumps to market, chasing Insulet’s Omnipod 5, the only FDA-cleared patch pump for type 1 and type 2 diabetes. Analysts expect tubeless models to eventually displace durable pumps.